Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing **Mefenamic acid**, a nonsteroidal anti-inflammatory drug (NSAID), and **Dicyclomine hydrochloride**, an anticholinergic antispasmodic. Mefenamic acid works by inhibiting prostaglandin synthesis, while dicyclomine reduces gastrointestinal smooth muscle activity.
## Primary Indications
* Symptomatic relief of abdominal pain associated with irritable bowel syndrome (IBS) and other gastrointestinal disorders characterized by smooth muscle spasm.
## Adult Dosing
* **Usual Adult Dose:** 1 tablet (containing mefenamic acid 250 mg and dicyclomine hydrochloride 20 mg) orally three times daily, with meals.
* **Maximum Adult Dose:** Consult local prescribing guidelines; generally, avoid exceeding recommended daily limits for individual components.
## Pediatric Dosing
* Data for pediatric use is limited. Meftal spas is generally **not recommended** for children. Consult specialist literature or local protocols if use is contemplated in specific pediatric populations, considering age and weight.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Mefenamic acid is renally excreted; monitor renal function closely. Dose reduction may be necessary.
* **Hepatic Impairment:** Use with caution. Mefenamic acid can exacerbate hepatic dysfunction. Monitor liver function.
* **Elderly:** Increased risk of adverse effects, particularly gastrointestinal bleeding and renal impairment. Use lower doses and monitor closely.
## Contraindications
* Hypersensitivity to mefenamic acid, dicyclomine, or other NSAIDs.
* Patients with active gastrointestinal ulceration or inflammation.
* History of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs.
* Severe renal or hepatic impairment.
* Myasthenia gravis.
* Glaucoma.
* Obstructive uropathy or gastrointestinal obstruction.
* Tachycardia, unstable heart failure.
* Infants less than 6 months of age.
## Adverse Effects
* **Common (Mefenamic Acid):** Diarrhea, nausea, vomiting, abdominal pain, dyspepsia, headache, dizziness, rash.
* **Common (Dicyclomine):** Dry mouth, blurred vision, constipation, urinary retention, drowsiness, confusion, tachycardia.
* **Serious:** Gastrointestinal bleeding, perforation, ulceration; renal failure; hepatic toxicity; Stevens-Johnson syndrome; anaphylaxis.
## Key Drug Interactions
* **NSAIDs:** Increased risk of gastrointestinal toxicity, renal impairment.
* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding.
* **Corticosteroids:** Increased risk of gastrointestinal bleeding.
* **Diuretics and Antihypertensives:** Reduced efficacy; increased risk of renal impairment.
* **Lithium:** Increased serum lithium levels.
* **Methotrexate:** Increased methotrexate toxicity.
* **Anticholinergics:** Additive anticholinergic effects.
* **Antacids:** May reduce absorption of mefenamic acid.
## Monitoring
* **Renal Function:** Baseline and periodic monitoring, especially in patients with risk factors.
* **Hepatic Function:** Baseline and periodic monitoring, especially in patients with risk factors.
* **Gastrointestinal Symptoms:** Monitor for signs and symptoms of bleeding or ulceration.
* **Hydration and Bowel Habits:** Monitor for signs of dehydration or worsening constipation/urinary retention.
## Clinical Pearls
* Administer with meals to minimize gastrointestinal upset.
* Due to the risk of serious adverse effects, use the lowest effective dose for the shortest duration necessary.
* Patients with pre-existing GI conditions, renal impairment, or cardiovascular disease should be closely monitored.
* The anticholinergic effects of dicyclomine can mask symptoms of gastrointestinal obstruction.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and local guidelines before initiating therapy. This summary does not replace a thorough patient assessment.
